Literature DB >> 16675583

Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses.

P Seshidhar Reddy1, Shanthi Ganesh, De-Chao Yu.   

Abstract

PURPOSE: The purpose of this study was to evaluate a fiber knob replacement strategy to improve infectivity and efficacy of Ad5 fiber chimeric oncolytic viruses for treatment of melanoma and head and neck cancers (HNC). EXPERIMENTAL
DESIGN: Adenoviral receptors and transduction levels were used to determine the level of infectivity of fiber-modified, green fluorescent protein-expressing, replication-deficient viruses in a panel of melanoma and HNC cell lines in vitro. Virus yield and cytotoxicity assays were used to determine the tumor specificity and virus replication-mediated cytotoxicity of the fiber-modified oncolytic viruses in the same panel of melanoma and HNC in vitro. Xenograft tumor models were used to assess the antitumor activity of those fiber-modified chimeric viruses compared with the parental virus.
RESULTS: Marker gene expression following gene transfer of the fiber chimeric vectors in melanoma and HNC cell lines was approximately 10-fold higher than that obtained with parental Ad5 vector. The fiber chimeric oncolytic variants mediated killing of melanoma and HNC cells that was 2- to 576-fold better than with the parental virus. In addition, fiber chimeric variants produced 2- to 7-fold more progeny virus in tumor cells than the parental virus. Moreover, a high multiplicity of infection was needed for the fiber chimeric viruses to produce cytotoxicity in normal cells. A significantly stronger antitumor response and survival advantage were shown in the tested melanoma and HNC xenograft models following i.t. injections.
CONCLUSIONS: In vitro and in vivo studies showed the improved transduction, replication, cytotoxicity, antitumor efficacy, and survival advantage in melanoma and HNC tumor models, suggesting a potential use of these oncolytic agents for the treatment of melanoma and HNCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675583     DOI: 10.1158/1078-0432.CCR-05-2397

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

Review 1.  Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism.

Authors:  J Michael Mathis; Phoebe L Stewart; Zheng B Zhu; David T Curiel
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

Review 2.  Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.

Authors:  Turang E Behbahani; Eben L Rosenthal; William B Parker; Eric J Sorscher
Journal:  Head Neck       Date:  2019-01-11       Impact factor: 3.147

Review 3.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

4.  Preparation of RGD-modified long circulating liposome loading matrine, and its in vitro anti-cancer effects.

Authors:  Xiao-yan Liu; Li-ming Ruan; Wei-wei Mao; Jin-qiang Wang; You-qing Shen; Mei-hua Sui
Journal:  Int J Med Sci       Date:  2010-06-14       Impact factor: 3.738

5.  Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.

Authors:  Hai-tao Meng; Lu Li; Hui Liu; Ying Wang; Gong-chu Li; Wen-bin Qian
Journal:  Acta Pharmacol Sin       Date:  2009-10-12       Impact factor: 6.150

6.  Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.

Authors:  Michael Robinson; Betty Li; Ying Ge; Derek Ko; Satya Yendluri; Thomas Harding; Melinda VanRoey; Katherine R Spindler; Karin Jooss
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

7.  Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus.

Authors:  Liangshun You; Ying Wang; Yingming Jin; Wenbin Qian
Journal:  Oncol Rep       Date:  2012-01-16       Impact factor: 3.906

Review 8.  The miRNAs Role in Melanoma and in Its Resistance to Therapy.

Authors:  Francesca Varrone; Emilia Caputo
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

Review 9.  Oncolytic virotherapy for head and neck cancer: current research and future developments.

Authors:  Akshiv Malhotra; Arun Sendilnathan; Matthew O Old; Trisha M Wise-Draper
Journal:  Oncolytic Virother       Date:  2015-07-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.